Completed PHASE3 INTERVENTIONAL 2-arm NCT00003746

Daily or Weekly Cladribine in Treating Patients With Hairy Cell Leukemia

Daily Versus Weekly Administration of 2-Chlorodeoxyadenosine (CDA) in Patients With Hairy Cell Leukemia

Sponsor: Swiss Cancer Institute

Conditions Leukemia

Interventions 2-chlorodeoxyadenosine (CDA) daily 2-chlorodeoxyadenosine weekly

Updated 6 times since 2017 Last updated: May 14, 2012 Started: Sep 30, 1998 Primary completion: Nov 30, 2005 Completion: Nov 30, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00003746, this PHASE3 trial focuses on Leukemia and remains completed. Sponsored by Swiss Cancer Institute, it has been updated 6 times since 1998, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

Aug 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Aug 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Sep 1998

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Swiss Cancer Institute

Data source: Swiss Cancer Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Bern, Switzerland